Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2024-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于会计师事务所2023年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2023 audit of 启迪药业集团股份公司. It details the qualifications, independence, quality control, audit procedures, and risk management of the auditor during the 2023 fiscal year audit. The document does not contain financial statements or results but focuses on the auditor's work and compliance with regulatory standards. This type of document is a standalone audit-related report assessing the auditor's performance and adherence to standards, which fits the category of Audit Report / Information (AR). The document length is 3121 characters, which is sufficient for a detailed audit evaluation report rather than a brief announcement. Therefore, the correct classification is AR with high confidence. FY 2023
2024-03-27 Chinese
关于公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 启迪药业集团股份公司 regarding the company's plan to apply for a comprehensive credit facility from banks. It details the proposed credit limit, purpose, and authorization for handling the credit application. The document is short (625 characters) and does not contain any financial statements, detailed financial data, or results. It is an update on financing activities, specifically about credit facilities and borrowing plans. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-03-27 Chinese
2023年年度财务报告
Annual Report Classification · 100% confidence The document is titled as a financial report for the year 2023, covering the period from January 1, 2023, to December 31, 2023. It contains detailed consolidated and parent company financial statements including balance sheets, income statements, cash flow statements, and statements of changes in equity. The length of the document is substantial (15,000 characters), and it includes comprehensive financial data and notes. This matches the characteristics of an official yearly report covering company activity and full financial performance, which corresponds to an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, and the content is clearly the full financial report itself. FY 2023
2024-03-27 Chinese
重大信息内部报告制度（2024年3月修订）
Governance Information Classification · 95% confidence The document is titled "重大信息内部报告制度" which translates to "Major Information Internal Reporting System" for a company. It outlines internal procedures and responsibilities for reporting significant information within the company, including definitions of what constitutes major information, reporting obligations, and management responsibilities. It references laws and regulations but does not contain financial statements, earnings data, or any form of financial results. It is a governance-related internal policy document rather than a financial report or announcement. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings that are more about external disclosures. The document is about internal governance and information disclosure procedures, which aligns best with Governance Information (CGR). The document length is over 6000 characters, so it is not a brief announcement or notice. Therefore, the classification is Governance Information (CGR) with high confidence.
2024-03-27 Chinese
关于2024年度对外担保额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the estimated external guarantee amount for the year 2024 by the company and its subsidiaries. It includes details about the guarantee parties, the guaranteed parties, financial data of subsidiaries, and board opinions approving the guarantee. The document references regulatory compliance with Shenzhen Stock Exchange listing rules and mentions the need for shareholder meeting approval. The content is focused on the company's external guarantee limits and related financial risk control, not a full financial report or earnings release. The document length is 4475 characters, which is relatively short and reads like a formal announcement rather than a comprehensive report. It does not contain full financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a certification or officer attestation. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about external guarantees and related board decisions, which do not fit other specific categories such as Capital/Financing Update or Management Reports. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-03-27 Chinese
关于股权收购业绩承诺实现情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the performance of a previously agreed acquisition-related profit commitment. It details the acquisition transaction, the profit targets set in the acquisition agreement, the actual profit performance audited by an accounting firm, and the resulting compensation obligations due to underperformance. It also discusses reasons for the shortfall and planned remedial measures. The document references an audit report but does not itself contain full financial statements or comprehensive financial data. It is primarily a disclosure about the status of an acquisition performance commitment and related compensation, not a full annual or interim financial report. The document length is about 2743 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of a Regulatory Filing (RNS) as it is a regulatory announcement about acquisition performance and compensation obligations, not a full audit report or annual report.
2024-03-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.